CorMedix Inc. (CRMD) stock
CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 15/3087% below fair value
$4.66−0.18 (-3.72%)
Close on Nov 13, 2026Market cap $363.22MP/E –Yield –
CorMedix ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.91M | -80.2% |
| Q2 FY2026 | Jun 30, 2026 | $53.45M | +163.5% |
| Q1 FY2026 | Mar 31, 2026 | $74.20M | – |
| Q3 FY2025 | Sep 30, 2025 | $55.14M | – |
| Q2 FY2025 | Jun 30, 2025 | $19.71M | – |
| Q1 FY2025 | Mar 31, 2025 | $20.29M | – |
See a number that looks wrong?